MediciNova is still recruiting adults with early-stage amyotrophic lateral sclerosis (ALS) for the COMBAT-ALS Phase 2b/3 clinical trial evaluating its investigational oral therapy MN-166 (ibudilast). Patients are being enrolled at 19 sites across North America; more information about contacts and locations is available here. “We continue to…
Clene, and its wholly owned subsidiary Clene Nanomedicine, have signed two lease agreements that will more than quadruple the manufacturing capacity of CNM-Au8, their investigational therapy for people with amyotrophic lateral sclerosis (ALS). The first lease is for a 10-year agreement for a 74,210-square-foot building in Elkton, Maryland.
Long-term treatment with Radicava (edaravone) is generally safe and nearly doubles survival time in adults with amyotrophic lateral sclerosis (ALS), according to a small real-life study in Japan. These data add to increasing, but still limited, evidence showing the therapy prolongs the life of ALS patients and…
Completing their version of 102 Olympic events — including archery, diving, and fencing — in 17 days, Stuart Bates and Charlotte Nichols raised some £150,000 (about $207,000) for the U.K.’s Motor Neurone Disease (MND) Association. The Oxfordshire duo wound up their grueling challenge, thought to be the first of…
Registration is now open for Global Genes‘ 2021 RARE Patient Advocacy Summit. This year’s hybrid event will be livestreamed from California Sept. 27-29, and some seats also are available for attending the event in person in San Diego. “Here you’ll have the opportunity to connect and engage with others…
Defects in cholesterol metabolism may account for some of the neurological damage that occurs in amyotrophic lateral sclerosis (ALS) and other diseases marked by problems with the protein TDP-43, a study reported. As cholesterol  is crucial to nerve cells, these results suggest that restoring its metabolism may be a…
It’s been a decade since the first UMass ALS Cellucci Fund team first participated in the Boston Marathon to raise funds to support University of Massachusetts Medical School (UMMS) researchers in their quest to find better treatments for amyotrophic lateral sclerosis (ALS). So, this year is significant. The…
Seelos Therapeutics has announced plans to start patient dosing in a pivotal Phase 2b/3 trial testing its experimental therapy SLS-005 (trehalose), designed to prevent protein clumping in cells, in adults with amyotrophic lateral sclerosis (ALS) by the close of September. The study is part of the HEALEY ALS Platform…
Rare mutations in the TP73 gene, which is involved in the regulation of a cell’s life cycle, may put a person at greater risk of amyotrophic lateral sclerosis (ALS), according to a genetic analysis of nearly 2,900 sporadic ALS patients. Such mutations were found to affect the maturation and survival of…
Registration is now open for the 2021 Rare Diseases and Orphan Products Breakthrough Summit, which will be held virtually Oct. 18–19. The event, also known as the National Organization for Rare Disorders (NORD) Summit, brings the rare disease community together to network and discuss developments in treatments and research…
Get regular updates to your inbox.